Dexcel Pharma Technologies Ltd. is > 10% Shareholder of Protalix BioTherapeutics, Inc.. Currently has a direct ownership of 3.64 Million shares of PLX, which is worth approximately $3.93 Million. The most recent transaction as insider was on Jun 03, 2021, when has been sold 857,506 shares (Common Stock) at a price of $2.25 per share, resulting in proceeds of $1,929,388. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 3.64M
0% 3M change
0% 12M change
Total Value Held $3.93 Million

Dexcel Pharma Technologies Ltd. Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 03 2021
SELL
Open market or private sale
$1,929,388 $2.25 p/Share
857,506 Reduced 19.08%
3,637,314 Common Stock
Jun 02 2021
SELL
Open market or private sale
$156,700 $2.56 p/Share
61,211 Reduced 1.34%
4,494,820 Common Stock

Also insider at

ROIV
Roivant Sciences Ltd. Healthcare
DPT

Dexcel Pharma Technologies Ltd.

> 10% Shareholder
Jerusalem, L3

Track Institutional and Insider Activities on PLX

Follow Protalix BioTherapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PLX shares.

Notify only if

Insider Trading

Get notified when an Protalix Bio Therapeutics, Inc. insider buys or sells PLX shares.

Notify only if

News

Receive news related to Protalix BioTherapeutics, Inc.

Track Activities on PLX